Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR302503 in Myelofibrosis
NCT01437787Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2011
- Primary completion
- Jun 2014
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of fedratinib in myelofibrosis (MF) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Response Rate at 24 weeks. Started Dec 2011; status: terminated.
02
Drugs
fedratinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT01437787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01437787.